Post by Thermo Fisher Scientific

Behind every transplant is a series of critical decisions. AI is helping clinicians navigate those decisions with greater speed, context and confidence, says Tina Liedtky, President of Transplant Diagnostics at Thermo Fisher Scientific. In MedCity News, Tina explores how artificial intelligence can help transplant teams turn complex data into clearer clinical insights. But in a field where patient outcomes depend on accuracy and consistency, adoption must be thoughtful. AI should support clinical teams, not replace them. Every model, workflow and output requires rigorous validation, strong governance and continued clinician oversight. AI also holds promise for enabling more personalized transplant care. By helping clinicians assess donor-recipient compatibility, identify immune risk factors and analyze patient trends over time, these technologies can support care plans tailored to each patient's unique needs. "The strongest AI adoption plans follow a simple pattern: start small, validate and scale only when results hold up across sites, shifts and real-world variation," Tina writes. The goal is safer, more personalized care, giving clinicians earlier signals, supporting more tailored monitoring and enabling more confident decisions for each patient. Read Tina's perspective on the future of AI in transplant diagnostics: https://lnkd.in/e-n6b4Kp